Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.840
-0.050 (-2.65%)
May 20, 2026, 4:00 PM EDT - Market closed

Fate Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2141272113699825,601
Market Cap Growth
95.33%-39.78%-42.88%-62.43%-82.47%-29.78%
Enterprise Value
116.43-3.489.5151.05649.195,094
Last Close Price
1.840.981.653.7410.0958.51
PS Ratio
33.9619.0915.465.8110.19100.29
PB Ratio
1.190.610.661.002.038.25
P/TBV Ratio
1.220.560.591.002.028.17
EV/Sales Ratio
18.43-0.520.702.386.7491.22
EV/EBITDA Ratio
-0.03----
EV/EBIT Ratio
-0.02----
EV/FCF Ratio
-0.03----
Debt / Equity Ratio
0.400.350.240.260.210.16
Net Debt / Equity Ratio
-0.55-0.61-0.61-0.57-0.67-0.74
Net Debt / EBITDA Ratio
0.770.931.011.231.112.37
Net Debt / FCF Ratio
0.911.121.571.531.152.35
Asset Turnover
0.020.020.030.100.120.07
Quick Ratio
5.725.677.348.114.167.68
Current Ratio
5.855.797.588.484.407.79
Return on Equity (ROE)
-67.15%-51.84%-54.21%-37.76%-48.46%-39.90%
Return on Assets (ROA)
-46.18%-38.89%-44.41%-31.44%-37.91%-28.11%
Return on Invested Capital (ROIC)
-150.10%-132.17%-145.16%-104.12%-133.60%-116.60%
Return on Capital Employed (ROCE)
-51.92%-43.12%-48.38%-35.99%-43.08%-31.52%
Buyback Yield / Dilution
-1.02%-4.49%-15.86%-1.34%-2.19%-15.01%
Total Shareholder Return
-1.02%-4.49%-15.86%-1.34%-2.19%-15.01%
Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q